April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent activity suggests that the FDA is taking a closer look at how pharmaceutical ...

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

If the crackdown on pharma’s TV ads and subsequent extension to social media has underscored anything, it’s that brands need ...

The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

The U.S. Centers for Medicare & Medicaid Services has pushed back application and agreement deadlines for its Medicaid drug pricing model, allowing drugmakers and states more preparation time. Pfizer ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.